TICAM1 and COVID-19: Due to elevated proinflammatory IL-6, IL-1β, and TNF-α in severe COVID-19 patients43, SARS-CoV-2 may activate TLR4 signaling with a bias towards the proinflammatory MyD88-dependent pathway rather than the anti-viral TRIF-dependent pathway39.